8-K 1 b71333rxe8vk.htm RXI PHARMACEUTICALS CORP FORM 8-K e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 18, 2008
RXI PHARMACEUTICALS CORPORATION
 
(Exact name of registrant as specified in its charter)
         
Delaware   001-33958   20-8099512
         
(State or other jurisdiction of
of incorporation or organization) 		  (Commission
File Number) 		  (I.R.S. Employer
Identification No.)
60 Prescott Street, Worcester, MA 01605
 
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (508) 767-3861
          Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 1.01 Entry into a Material Definitive Agreement
Item 9.01 Financial Statements and Exhibits.
Signature
Index to Exhibits
EX-99.1 RXi Pharmaceuticals Corporation 2007 Incentive Plan, as amended

Table of Contents

Item 1.01 Entry into a Material Definitive Agreement
          On July 18, 2008, the stockholders of RXi Pharmaceuticals Corporation (the “Company”) approved the amendment (the “Incentive Plan Amendment”) to the RXi Pharmaceuticals Corporation 2007 Incentive Plan, (the “2007 Incentive Plan”), which increases the number of shares of the Company’s common stock available under the 2007 Incentive Plan. The Company’s Board of Directors had previously approved the Incentive Plan Amendment, subject to the approval of the stockholders. A copy of the 2007 Incentive Plan, as amended, is attached to this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1   RXi Pharmaceuticals Corporation 2007 Incentive Plan, as amended

 

Table of Contents

Signature
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  RXI PHARMACEUTICALS CORPORATION
 		  
Date: July 24, 2008  By:   /s/ Stephen J. DiPalma    
    Name:   Stephen J. DiPalma   
    Title:   Chief Financial Officer   
 

 

Table of Contents

Index to Exhibits
99.1   RXi Pharmaceuticals Corporation 2007 Incentive Plan, as amended